Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IMCR, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Tebentafusp (IMCgp100) FDA approved Jan 2022 · Kimmtrak |
Advanced Melanoma | Phase 3 · NCT05549297 | Recruiting |
| Brenetafusp | Advanced Melanoma | Phase 3 · NCT06112314 | Recruiting |
| Investigators Choice | Advanced Melanoma | Phase 3 · NCT05549297 | Recruiting |
| Monoclonal Antibody | Cancer | Phase 1/2 · NCT06840119 | Recruiting |
| Kinase Inhibitor | Cancer | Phase 1/2 · NCT06840119 | Recruiting |
| Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso | Select Advanced Solid Tumors | Phase 1/2 · NCT03515551 | Terminated |
| IMC-R117C | Cancer | Phase 1/2 · NCT06840119 | Recruiting |
| Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv… | Select Advanced Solid Tumors | Phase 1/2 · NCT03973333 | Withdrawn |
| Chemotherapy drug | Cancer | Phase 1/2 · NCT06840119 | Recruiting |
| Angiogenesis Inhibitor | Cancer | Phase 1/2 · NCT06840119 | Recruiting |
| IMC-P115C | PRAME Positive | Phase 1 · NCT07156136 | Recruiting |
| IMC-I109V Single Ascending Dose | Hepatitis B, Chronic | Phase 1 · NCT05867056 | Withdrawn |
| IMC-S118AI | Type 1 Diabetes | Phase 1 · NCT07493122 | Not yet recruiting |
| IMC-I109V Multiple Ascending Doses | Hepatitis B, Chronic | Phase 1 · NCT05867056 | Withdrawn |
| HBV HCC Module MAD | Hepatitis B, Chronic | Phase 1 · NCT05867056 | Withdrawn |
Also used in these trials (approved or third-party drugs, not IMCR's own candidates): Relatlimab, Nivolumab, Atezolizumab, Pembrolizumab, Ipilimumab, Dexamethasone, Dacarbazine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
IMCR holds $901.3M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IMCR files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Wellington Management Group LLP | Institution (13G, 5%+) | 5,959,773 | 11.53% | 2026-06-30 |
| Point72 Asset Management, L.P. | 5%+ holder (13G) | 2,720,043 | 5.26% | 2026-11-06 |
| BAKER BROS. ADVISORS LP Director · +39,123 options |
Insider | 2,144,060 | 4.15% | 2025-03-17 |
| Bahija Jallal CHIEF EXECUTIVE OFFICER, Director · +889,463 options |
Insider | 12,343 | 0.02% | 2026-02-17 |
| David M Berman HEAD OF R&D · +176,823 options |
Insider | 5,859 | 0.01% | 2026-02-17 |
| Leger Tina Amber St CHIEF HR OFFICER · +29,569 options |
Insider | 1,119 | 0.00% | 2026-02-17 |
| John Goll SVP, FINANCE & CAO · +43,465 options |
Insider | 653 | 0.00% | 2026-02-17 |
Share count 51,681,376 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMCR and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →